56. ベーチェット病 Behcet disease Clinical trials / Disease details


臨床試験数 : 76 薬物数 : 111 - (DrugBank : 32) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02756650
(ClinicalTrials.gov)
June 23, 201631/3/20161 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular InvolvementAn Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behçet's Disease Patients With Neurologic or Vascular InvolvementBehcet DiseaseDrug: CanakinumabNovartis PharmaceuticalsNULLCompleted18 Years60 YearsAll8Phase 2Turkey
2EUCTR2010-024152-29-DE
(EUCTR)
02/09/201121/06/2011An open-label study to evaluate efficacy and tolerability of Canakinumab in patients with Behçet Disease who do not respond to standard treatment (Eine offene Studie zur Wirksamkeit und Verträglichkeit von Canakinumab bei Patienten mit Morbus Behçet, die auf die übliche Behandlung nicht ansprechen)Canakinumab for Behçet`s Disease Resistant to Standard Treatment(CanBeDisT) - CanBeDisT Behçet`s Disease
MedDRA version: 14.0;Level: PT;Classification code 10004213;Term: Behcet's syndrome;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Ilaris
Product Name: Ilaris
INN or Proposed INN: CANAKINUMAB
University Hospital of TübingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
10Germany